News | March 05, 2012

SciFluor Extends License With Harvard to Advance Use of PET Imaging

March 5, 2012 — SciFluor Life Sciences announced an agreement with Harvard University that extends its license of proprietary fluorine technology to the rapidly growing field of positron emission tomography (PET) imaging. Under the new agreement, SciFluor gains access to technology that enables the rapid, efficient synthesis of 18F-labeled molecules, which empower PET imaging for a new level of informed and predictive drug development. The company previously announced an exclusive, worldwide license from Harvard University to various fluorination methods and to a portfolio of novel fluorinated compounds.

“We are pleased to further expand the breadth of our innovative fluorine technologies and to extend our licensing agreement with Harvard,” said Arthur Hiller, CEO of SciFluor Life Sciences. “With this new technology, SciFluor is now capable of developing sophisticated 18F PET tracers that were previously inaccessible. This advance paves the way to significantly expand the capabilities of PET imaging in the drug discovery and development process by providing researchers with new insights into a drug candidate’s potential efficacy, safety and optimal dosing. Our initial focus will be on identifying industry partnerships between SciFluor and companies with drug pipelines and research priorities that benefit from applying this fluorination technology, which ultimately could result in shorter development times, improved clinical trial designs and more revolutionary therapies for patients.”

By utilizing SciFluor technology in PET imaging, researchers will now be able to observe a broader range of a drug’s cellular and metabolic activity in vivo to determine, for example, the drug’s capacity to cross the blood-brain barrier, its ability to hit the relevant biological targets, and the drug’s dose effectiveness and potential clinical benefit.

This newly licensed technology was recently described in the paper, “A Fluoride-Derived Electrophilic Late-Stage Fluorination Reagent for PET Imaging,” published in the Nov. 4, 2011, issue of Science and co-authored by Tobias Ritter, Ph.D., founder and chief technology officer of SciFluor.

For more information: www.scifluor.com

Related Content

Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....